{"entity":{"id":"abexinostat","kind":"drug","name":"Abexinostat","aka":[],"tldr":"Abexinostat is an experimental small-molecule drug from Xynomic Pharmaceuticals in phase 3 trials for renal cell carcinoma, diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.","summary":"Abexinostat (PCI-24781) is a small-molecule drug developed by Xynomic Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT03592472 (A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)), in renal cell carcinoma, diffuse large B-cell lymphoma, follicular lymphoma and hodgkin lymphoma. The largest, NCT03592472, plans to enrol 413 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Abexinostat","url":"https://clinicaltrials.gov/search?intr=PCI-24781"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","dlbcl","follicular-lymphoma","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["xynomic-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["renaviv","nct03600441","nct03936153","nct04024696","nct03934567"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PCI-24781","modality":"small molecule","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/abexinostat/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"company":[{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/"}],"trial":[{"id":"nct04024696","kind":"trial","name":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","route":"/trials/nct04024696/"},{"id":"nct03934567","kind":"trial","name":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03934567/"},{"id":"renaviv","kind":"trial","name":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","route":"/trials/renaviv/"},{"id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/"},{"id":"nct03936153","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct03936153/"}]}}